Document is current
Any future updates will be listed below
-
Authors
Del Re, Marzia
Crucitta, Stefania
Paolieri, Federico
Cucchiara, Federico
Verzoni, Elena
Bloise, Francesco
Ciampi, Raffaele
Mercinelli, Chiara
Capuano, Annalisa
Sportiello, Liberata
Martinetti, Antonia
Procopio, Giuseppe
Galli, Luca
Porta, Camillo
Bracarda, Sergio
Danesi, Romano https://orcid.org/0000-0002-4414-8934
-
Funding
Funding for this research was provided by:
Ministero dell'Università e della Ricerca (2017NRW5K_002)
Novartis
- License Information
-
More Information
Article History
Received: 9 May 2022
Accepted: 25 July 2022
First Online: 16 August 2022
Declarations
:
: This study was approved by the Ethics committee of Area Vasta Nord-Ovest, Pisa, Italy (Study Number 716/2015, Protocol No. 42847) and patients gave their written consent to participate.
: Not applicable.
: Marzia Del Re—consultant/speaker: Astellas, AstraZeneca, Celgene, Novartis, Pfizer, Bio-Rad, Janssen, Sanofi-Aventis, Ipsen, Roche Elena Verzoni—consultant/advisor: Ipsen, Merck, Novartis, Pfizer. Giuseppe Procopio—consultant advisor: Astra Zeneca, Bayer, Bristol Myers Squibb, Ipsen, Merck, Novartis, Pfizer; research grants: Ipsen, Novartis. Camillo Porta—consultant/speaker: Angelini, AstraZeneca, Bristol Myers Squibb, Eisai, EUSAPharma, General Electric, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer; expert testimony: EUSAPharma, Pfizer; Protocol Steering Committee Member: Bristol Myers Squibb, Eisai, EUSAPharma. Romano Danesi—consultant/speaker: Ipsen, Novartis, Pfizer, Sanofi Genzyme, AstraZeneca, Janssen, Gilead, Lilly, Gilead and EUSAPharma.
